Kyntra Bio, Inc
Kyntra Bio, Inc. is a U.S.-based pharmaceutical preparations company focused on developing, manufacturing, and commercializing roxadustat and other product candidates through collaborations and third-party partners. The business model combines drug product supply, development services, and collaboration revenue, with meaningful exposure to China, Japan, Europe, and other international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSales of commercial-grade API and bulk drug product, mainly roxadustat, to partners for launch and commercialization.
Co-development and other development-related services billed to partners during clinical and regulatory work.
Variable consideration tied to partner progress and downstream product sales under collaboration agreements.
Contract manufacturing, patent transfer, and sales of research and development materials.
Products
Reported · share of revenue- Drug Product Revenue90.8 %
- Development and Other Revenue9.2 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company sells primarily to pharmaceutical collaboration partners rather than to end patients, with AstraZeneca, Astellas, and Falikang highlighted in the filings. Its commercial customers use Kyntra Bio’s product supply to support pre-commercial preparation, regulatory launches, and ongoing sales in China, Japan, Europe, and other markets.
AstraZeneca and Astellas buy drug product and related services to support development, launch, and commercialization.
Falikang purchases roxadustat product for distribution in China and accounts for most direct product revenue.
Hospitals and physicians are the end-market gatekeepers for adoption, especially in China.
Clinical sites and investigators support development programs and patient recruitment for product candidates.
Strategy
The company’s near-term focus is to preserve liquidity, complete asset sales or financing actions, and keep core commercialization and supply relationships functioning. Longer term, it is trying to sustain roxadustat value in key markets while advancing FG-3246 and other pipeline assets, but execution depends heavily on partners, regulators, and manufacturing continuity.
The company disclosed substantial doubt about going concern and needs cash to fund operations and debt obligations.
Roxadustat remains the main revenue driver and supports collaboration and supply economics.
Pipeline success is needed to diversify away from a single product and create future value.
Geography
2025Kyntra Bio operates across the U.S., China, Japan, Europe, and other international markets through partners and third-party manufacturers. China remains strategically important because of roxadustat commercialization, manufacturing, and cash flow exposure, while Japan and Europe matter for Astellas-related supply and launch activity.
Share of the revenue the company reports by geography.
Risks
The company faces high execution risk because revenue depends on a small number of collaborations, third-party manufacturers, and regulatory outcomes. It also has material liquidity and going-concern risk, plus China-specific exposure to anti-corruption enforcement, foreign exchange controls, geopolitical tensions, and intellectual property enforcement challenges.
- Substantial doubt about going concernImpact: CriticalLikelihood: High
The company disclosed that it may not have sufficient liquidity without asset sales, China cash access, or new financing.
Exposure: U.S. operations and debt service
- Dependence on roxadustat and a small partner baseImpact: HighLikelihood: High
A large share of value and revenue is tied to one lead product and a few commercial collaborators.
Exposure: Commercial revenue and pipeline valuation
- Third-party manufacturing and clinical trial relianceImpact: HighLikelihood: High
The company does not have its own operating manufacturing facilities and depends on external vendors for supply and trials.
Exposure - Geopolitical and regulatory risk in ChinaImpact: HighLikelihood: Medium
U.S.-China tensions, foreign exchange controls, and China policy changes can disrupt operations and cash repatriation.
Exposure - Generic and competitive pressureImpact: MediumLikelihood: High
Competing products and generics can reduce pricing power and market acceptance after patent expiry.
Exposure: Roxadustat and future candidates
- China anti-corruption and hospital access riskImpact: MediumLikelihood: Medium
Anti-corruption campaigns can limit hospital access for sales representatives and reduce commercialization effectiveness.
Exposure: China sales and promotion
Accounting
Judgemental itemsRevenue depends on transfer of control, billing timing, and variable consideration estimates under partner contracts.
Impact: Can shift revenue between quarters and affect comparability
Product revenue is included in discontinued operations in the filings, affecting how investors read core revenue trends.
Impact: Changes reported top-line comparability
The NovaQuest RIFA creates a liability that is repaid from future revenue streams and affects cash flow presentation.
Impact: Impacts leverage, liquidity, and future revenue allocation
Drug product revenue may be adjusted if actual consideration differs from estimates.
Impact: Can create revenue true-ups and margin volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
Lisata Therapeutics, Inc
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Minerva Neurosciences, Inc.
NERV · Pharmaceutical Preparations
Septerna, Inc.
SEPN · Pharmaceutical Preparations
Septerna is a U.S.-based biotechnology company focused on discovering and developing small-molecule medicines for diseases driven by G protein-coupled receptors (GPCRs).
KalVista Pharmaceuticals, Inc.
Pharmaceutical Preparations
KalVista Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing oral therapies for hereditary angioedema (HAE).
ZyVersa Therapeutics, Inc.
ZVSA · Pharmaceutical Preparations
Last updated: 24/09/2026